Lipocine (LPCN) Announces Launch Of Public Offering Of Common Stock

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Lipocine.

We intend to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include additions to working capital and capital expenditures.

Raymond James & Associates, Inc. is acting as sole manager for the public offering.

You May Also Be Interested In

• INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh
• Raymond James Financial (RJF) Tops Q2 EPS by 1c
• Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio